Premium
A multicenter double‐blind placebo‐controlled trial of pergolide as an adjunct to sinemet® in Parkinson's disease
Author(s) -
Olanow C. W.,
Fahn S.,
Muenter M.,
Klawans H.,
Hurtig H.,
Stern M.,
Shoulson I.,
Kurlan R.,
Grimes J. D.,
Jankovic J.,
Hoehn M.,
Markham C. H.,
Duvisin R.,
Reinmuth O.,
Leonard H. A.,
Ahlskog E.,
Feldman R.,
Hershey L.,
Yahr M. D.
Publication year - 1994
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.870090107
Subject(s) - pergolide , levodopa , parkinson's disease , placebo , medicine , dyskinesia , anesthesia , dopamine agonist , psychology , dopamine , disease , dopaminergic , alternative medicine , pathology
Abstract Three hundred and seventy‐six subjects with advanced Parkinson's disease participated in a prospective, double‐blind placebo‐controlled study of the dopamine agonist pergolide mesylate as an adjunct to Sinemet®. At 6 months, patients randomized to pergolide had a statistically singnificant improvement in total Parkinson's score, scores of activities of daily living, motor function, number of “off” hours, Hoehn and Yahr stage, and numerous parameters of parkinsonian function including bradykinesia, rigidity, gait, and dexterity. This benefit was obtained with the addition of a mean dose of 2.94 mg of pergolide, which permitted a 24.7% reduction in dose of levodopa. Adverse reactions were, for the most part, mild, reversible, and not of major clinical significance. No significant cardiac or electrocardiographic abnormalities were detected. This study demonstrates that pergolide mesylate, as an adjunct to levodopa, is an effective antiparkinsonian agent that provides clinical improvement while permitting a reduction in levodopa dose.